| Autor: |
Ndhlovu LC; Division of Experimental Medicine, Department of Medicine, University of California at San Francisco, San Francisco, CA 94110, USA. lndhlovu@medsfgh.ucsf.edu, Snyder-Cappione JE, Carvalho KI, Leal FE, Loo CP, Bruno FR, Jha AR, Devita D, Hasenkrug AM, Barbosa HM, Segurado AC, Nixon DF, Murphy EL, Kallas EG |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical and experimental immunology [Clin Exp Immunol] 2009 Dec; Vol. 158 (3), pp. 294-9. Date of Electronic Publication: 2009 Sep 02. |
| DOI: |
10.1111/j.1365-2249.2009.04019.x |
| Abstrakt: |
Human T lymphotropic virus type 1 (HTLV-1) infects 10-20 million people worldwide. The majority of infected individuals are asymptomatic; however, approximately 3% develop the debilitating neurological disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). There is also currently no cure, vaccine or effective therapy for HTLV-1 infection, and the mechanisms for progression to HAM/TSP remain unclear. NK T cells are an immunoregulatory T cell subset whose frequencies and effector functions are associated critically with immunity against infectious diseases. We hypothesized that NK T cells are associated with HAM/TSP progression. We measured NK T cell frequencies and absolute numbers in individuals with HAM/TSP infection from two cohorts on two continents: São Paulo, Brazil and San Francisco, CA, USA, and found significantly lower levels when compared with healthy subjects and/or asymptomatic carriers. Also, the circulating NK T cell compartment in HAM/TSP subjects is comprised of significantly more CD4(+) and fewer CD8(+) cells than healthy controls. These findings suggest that lower numbers of circulating NK T cells and enrichment of the CD4(+) NK T subset are associated with HTLV-1 disease progression. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
